Last reviewed · How we verify

phylloquinone (K1) — Competitive Intelligence Brief

phylloquinone (K1) (phylloquinone (K1)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin K supplement / Cofactor. Area: Nutrition / Metabolic Disorders.

phase 3 Vitamin K supplement / Cofactor Gamma-glutamyl carboxylase (GGCX) Nutrition / Metabolic Disorders Small molecule Live · refreshed every 30 min

Target snapshot

phylloquinone (K1) (phylloquinone (K1)) — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Phylloquinone (vitamin K1) acts as a cofactor for gamma-glutamyl carboxylase, enabling the post-translational carboxylation of glutamic acid residues in vitamin K-dependent proteins involved in coagulation, bone metabolism, and vascular health.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
phylloquinone (K1) TARGET phylloquinone (K1) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) phase 3 Vitamin K supplement / Cofactor Gamma-glutamyl carboxylase (GGCX)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin K supplement / Cofactor class)

  1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). phylloquinone (K1) — Competitive Intelligence Brief. https://druglandscape.com/ci/phylloquinone-k1. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: